No matches

17 search results for: disease progression

UEGW 2024 | WHAT Can Be Used to Monitor Treatment Response in EoE and WHEN?
Gastroenterology
UEGW 2024 | WHAT Can Be Used to Monitor Treatment Response in EoE and WHEN?
expert video

Dr. Milli Gupta emphasizes the need to regularly monitor multiple disease domains when assessing treatment response, not just EoE symptoms.

View more
Interplay of Barrier Dysfunction and Type 2 Inflammation in EoE
Gastroenterology
Interplay of Barrier Dysfunction and Type 2 Inflammation in EoE
expert video

Learn from Prof. Seema Aceves about the interconnectivity of type 2 inflammation and barrier dysfunction in mediating EoE pathophysiology.

View more
Gastro Forum 2025 | EoE: How Far We've Come
Gastroenterology
Gastro Forum 2025 | EoE: How Far We've Come
videoanimation

Prof. Salvatore Oliva and Dr. Milli Gupta discuss the evolution in understanding EoE and the impact of chronic, underlying type 2 inflammation.

View more
Coverpage
Congress
8
March
2024
Congress
ADVENT at San Diego, 2024

Two educational symposia at San Diego, 2024, explore the role of type 2 inflammation and the related manifestations in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

View more
European EoE Day 2024 | May 22
Awareness Day
22
May
2024
Awareness Day
European EoE Day 2024 | May 22

In recognition of European EoE Day, ADVENT is providing medical education resources to increase awareness of eosinophilic esophagitis (EoE).

View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: LebanonChange country/region